Current HIV/AIDS Reports

, Volume 15, Issue 2, pp 120–126 | Cite as

Role of Noncommunicable Diseases (NCDs) in Resource-Limited Settings (RLS)

  • Mosepele Mosepele
  • Elizabeth Botsile
HIV Pathogenesis and Treatment (AL Landay and N Utay, Section Editors)
Part of the following topical collections:
  1. Topical Collection on HIV Pathogenesis and Treatment


Purpose of Review

As access to effective antiretroviral therapy (ART) expands globally, a decline in AIDS-related morbidity and mortality has been complicated by rising rates of noncommunicable diseases (NCDs). This review provides a brief description of NCDs and existing gaps on knowledge about NCDs among HIV-infected adults mostly in Africa.

Recent findings

Recent reports show that one in every five persons living with HIV has a chronic illness, predominantly diabetes and/or hypertension, depression, and most of these conditions are either not diagnosed or not being managed. Human papilloma virus-associated anal dysplasia occurs among 70% of HIV-infected women in RLS. Recognizing risk factors for NCDs and providing effective screening and optimal care remains challenging.


Research is urgently needed to carefully characterize HIV-associated NCDs in RLS. Such studies should provide a framework for high-priority NCDs that the limited resources can be focused on in these settings.


Noncommunicable diseases HIV Resource-limited settings 


Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no competing interests.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Streatfield PK, Khan WA, Bhuiya A, Hanifi SMA, Alam N, Millogo O, et al. HIV/AIDS-related mortality in Africa and Asia: evidence from INDEPTH health and demographic surveillance system sites. Glob Health Action. 2014;7(1):25370. Scholar
  2. 2.
    van Heerden A, Barnabas RV, Norris SA, Micklesfield LK, van Rooyen H, Celum C. High prevalence of HIV and non-communicable disease (NCD) risk factors in rural KwaZulu-Natal, South Africa. J Int AIDS Soc. 2017;20(2).
  3. 3.
    Kagaruki GB, Mayige MT, Ngadaya ES, Kimaro GD, Kalinga AK, Kilale AM, et al. Magnitude and risk factors of non-communicable diseases among people living with HIV in Tanzania: a cross sectional study from Mbeya and Dar es Salaam regions. BMC Public Health. 2014;14(1):904. Scholar
  4. 4.
    Kavishe B, Biraro S, Baisley K, Vanobberghen F, Kapiga S, Munderi P, et al. High prevalence of hypertension and of risk factors for non-communicable diseases (NCDs): a population based cross-sectional survey of NCDS and HIV infection in Northwestern Tanzania and Southern Uganda. BMC Med. 2015;13(1):126. Scholar
  5. 5.
    Magodoro IM, Esterhuizen TM, Chivese T. A cross-sectional, facility based study of comorbid non-communicable diseases among adults living with HIV infection in Zimbabwe. BMC Res Notes. 2016;9(1):379. Scholar
  6. 6.
    Malaza A, Mossong J, Barnighausen T, Newell ML. Hypertension and obesity in adults living in a high HIV prevalence rural area in South Africa. PLoS One. 2012;7(10):e47761. Scholar
  7. 7.
    Mondo CK, Otim MA, Akol G, Musoke R, Orem J. The prevalence and distribution of non-communicable diseases and their risk factors in Kasese district, Uganda. Cardiovasc J Africa. 2013;24(3):52–7. Scholar
  8. 8.
    Oladapo OO, Salako L, Sodiq O, Shoyinka K, Adedapo K, Falase AO. A prevalence of cardiometabolic risk factors among a rural Yoruba south-western Nigerian population: a population-based survey. Cardiovasc J Africa. 2010;21(1):26–31.Google Scholar
  9. 9.
    Wand H, Ramjee G. High prevalence of obesity among women who enrolled in HIV prevention trials in KwaZulu-Natal, South Africa: healthy diet and life style messages should be integrated into HIV prevention programs. BMC Public Health. 2013;13(1):159. Scholar
  10. 10.
    Bloomfield GS, Khazanie P, Morris A, Rabadan-Diehl C, Benjamin LA, Murdoch D, et al. HIV and noncommunicable cardiovascular and pulmonary diseases in low- and middle-income countries in the ART era: what we know and best directions for future research. J Acquir Immune Defic Syndr. 2014;67(Suppl 1):S40–53. Scholar
  11. 11.
    Siedner MJ. Aging, health, and quality of life for older people living with HIV in sub-Saharan Africa: a review and proposed conceptual framework. J Aging Health. 2017:898264317724549.
  12. 12.
    Oliveira RVC, Shimakura SE, Campos DP, Hokerberg YHM, Victoriano FP, Ribeiro S, et al. Effects of antiretroviral treatment and nadir CD4 count in progression to cardiovascular events and related comorbidities in a HIV Brazilian cohort: a multi-stage approach. AIDS Care. 2017:1–9.
  13. 13.
    Holloway CJ, Boccara F. HIV-related cardiovascular disease: closing the gap in mortality. Curr Opin HIV AIDS. 2017;12(6):509–12. Scholar
  14. 14.
    Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab. 2007;92(7):2506–12. Scholar
  15. 15.
    Triant VA, Grinspoon SK. Epidemiology of ischemic heart disease in HIV. Curr Opin HIV AIDS. 2017;12(6):540–7. Scholar
  16. 16.
    Raposeiras-Roubin S, Triant V. Ischemic heart disease in HIV: an in-depth look at cardiovascular risk. Rev Esp Cardiol (English ed). 2016;69(12):1204–13. Scholar
  17. 17.
    Srinivasa S, Lu MT, Fitch KV, Hallett TR, O'Malley TK, Stone LA, et al. Epicardial adipose tissue volume and cardiovascular risk indices among asymptomatic women with and without HIV. Antivir Ther. 2017.
  18. 18.
    Triant VA. Cardiovascular disease and HIV infection. Curr HIV/AIDS Rep. 2013;10(3):199–206. Scholar
  19. 19.
    Triant VA. Epidemiology of coronary heart disease in patients with human immunodeficiency virus. Rev Cardiovasc Med. 2014;15(Suppl 1):S1–8. Scholar
  20. 20.
    Holloway CJ, Ntusi N, Suttie J, Mahmod M, Wainwright E, Clutton G, et al. Comprehensive cardiac magnetic resonance imaging and spectroscopy reveal a high burden of myocardial disease in HIV patients. Circulation. 2013;128(8):814–22. Scholar
  21. 21.
    • Benjamin LA, Corbett EL, Connor MD, Mzinganjira H, Kampondeni S, Choko A, et al. HIV, antiretroviral treatment, hypertension, and stroke in Malawian adults: a case-control study. Neurology. 2016;86(4):324–33. This is the most recent and largest case-control study of stroke among 725 HIV-infected adults in Malawi. This study showed that HIV was an independent risk factor for stroke. However, traditional CVD risk factors contributed most risk among older HIV-infected patients who experienced stroke. CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Benjamin LA, Allain TJ, Mzinganjira H, Connor MD, Smith C, Lucas S, et al. The role of human immunodeficiency virus-associated vasculopathy in the etiology of stroke. J Infect Dis. 2017;216(5):545–53. Scholar
  23. 23.
    Huis In’t Veld D, Pengpid S, Colebunders R, Peltzer K. Body mass index and waist circumference in patients with HIV in South Africa and associated socio-demographic, health related and psychosocial factors. AIDS Behav 2017.
  24. 24.
    Mosepele M, Letsatsi V, Mokgatlhe L, Hudson FP, Gross R. Cholesterol screening and statin prescription is low among HIV-infected patients on protease-inhibitor regimens in Botswana. Open AIDS J. 2017;11(1):45–51. Scholar
  25. 25.
    Julius H, Basu D, Ricci E, Wing J, Basu JK, Pocaterra D, et al. The burden of metabolic diseases amongst HIV positive patients on HAART attending The Johannesburg Hospital. Curr HIV Res. 2011;9(4):247–52. Scholar
  26. 26.
    Peck RN, Shedafa R, Kalluvya S, Downs JA, Todd J, Suthanthiran M, et al. Hypertension, kidney disease, HIV and antiretroviral therapy among Tanzanian adults: a cross-sectional study. BMC Med. 2014;12(1):125. Scholar
  27. 27.
    Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63(25 Pt B):2889–934. Scholar
  28. 28.
    Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of The National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA. 2001;285(19):2486–97.CrossRefGoogle Scholar
  29. 29.
    Mosepele M, Hemphill LC, Palai T, Nkele I, Bennett K, Lockman S, et al. Cardiovascular disease risk prediction by the American College of Cardiology (ACC)/American Heart Association (AHA) Atherosclerotic Cardiovascular Disease (ASCVD) risk score among HIV-infected patients in sub-Saharan Africa. PLoS One. 2017;12(2):e0172897. Scholar
  30. 30.
    • Hyle EP, Mayosi BM, Middelkoop K, Mosepele M, Martey EB, Walensky RP, et al. The association between HIV and atherosclerotic cardiovascular disease in sub-Saharan Africa: a systematic review. BMC public health. 2017;17(1):954. A recent meta-analysis of all studies on atherosclerotic CVD in Africa. The analysis revealed that most work on atherosclerotic CVD in Africa has focused on intermediary (pre-clinical) markers of CVD but not clinical end-points. The review reports increased signal for CVD. CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Raghavan A, Rimmelin DE, Fitch KV, Zanni MV. Sex differences in select non-communicable HIV-associated comorbidities: exploring the role of systemic immune activation/inflammation. Curr HIV/AIDS Rep. 2017;14(6):220–8. Scholar
  32. 32.
    Longenecker CT, Sullivan C, Baker JV. Immune activation and cardiovascular disease in chronic HIV infection. Curr Opin HIV AIDS. 2016;11(2):216–25. Scholar
  33. 33.
    Hileman CO, Funderburg NT. Inflammation, immune activation, and antiretroviral therapy in HIV. Curr HIV/AIDS Rep. 2017;14(3):93–100. Scholar
  34. 34.
    Duffau P, Wittkop L, Lazaro E, le Marec F, Cognet C, Blanco P, et al. Association of immune-activation and senescence markers with non-AIDS-defining comorbidities in HIV-suppressed patients. AIDS (London, England). 2015;29(16):2099–108. Scholar
  35. 35.
    Gomez-Mora E, Massanella M, Garcia E, Giles D, Bernado M, Urrea V, et al. Elevated humoral response to cytomegalovirus in HIV-infected individuals with poor CD4+ T-cell immune recovery. PLoS One. 2017;12(9):e0184433. Scholar
  36. 36.
    Freeman ML, Lederman MM, Gianella S. Partners in crime: the role of CMV in immune dysregulation and clinical outcome during HIV infection. Curr HIV/AIDS Rep. 2016;13(1):10–9. Scholar
  37. 37.
    Christensen-Quick A, Vanpouille C, Lisco A, Gianella S. Cytomegalovirus and HIV persistence: pouring gas on the fire. AIDS Res Hum Retrovir. 2017;33(S1):S23–s30. Scholar
  38. 38.
    Gronborg HL, Jespersen S, Honge BL, Jensen-Fangel S, Wejse C. Review of cytomegalovirus coinfection in HIV-infected individuals in Africa. Rev Med Virol. 2017;27(1).
  39. 39.
    • Huaman MA, Ticona E, Miranda G, Kryscio RJ, Mugruza R, Aranda E, et al. The relationship between latent tuberculosis infection and acute myocardial infarction. Clin Infect Dis. 2017. This is a case-control study of acute myocardial infarction (AMI) among adults in Lima, Peru. The study revealed an almost twofold increase in the risk for among those with latent tuberculosis infection (LTBI). This association, if confirmed by others, will have an implication in Africa where LTBI rates can be as high as 27%.
  40. 40.
    Houben RM, Dodd PJ. The global burden of latent tuberculosis infection: a re-estimation using mathematical modelling. PLoS Med. 2016;13(10):e1002152. Scholar
  41. 41.
    Moscicki AB, Yao TJ, Ryder MI, Russell JS, Dominy SS, Patel K, et al. The burden of oral disease among perinatally HIV-infected and HIV-exposed uninfected youth. PLoS One. 2016;11(6):e0156459. Scholar
  42. 42.
    Monaco CL, Gootenberg DB, Zhao G, Handley SA, Ghebremichael MS, Lim ES, et al. Altered virome and bacterial microbiome in human immunodeficiency virus-associated acquired immunodeficiency syndrome. Cell Host Microbe. 2016;19(3):311–22. Scholar
  43. 43.
    PrayGod G, Blevins M, Woodd S, Rehman AM, Jeremiah K, Friis H, et al. A longitudinal study of systemic inflammation and recovery of lean body mass among malnourished HIV-infected adults starting antiretroviral therapy in Tanzania and Zambia. Eur J Clin Nutr. 2016;70(4):499–504. Scholar
  44. 44.
    Canipe A, Chidumayo T, Blevins M, Bestawros M, Bala J, Kelly P, et al. A 12 week longitudinal study of microbial translocation and systemic inflammation in undernourished HIV-infected Zambians initiating antiretroviral therapy. BMC Infect Dis. 2014;14(1):521. Scholar
  45. 45.
    Bestawros M, Chidumayo T, Blevins M, Canipe A, Bala J, Kelly P, et al. Increased systemic inflammation is associated with cardiac and vascular dysfunction over the first 12 weeks of antiretroviral therapy among undernourished, HIV-infected adults in Southern Africa. J AIDS Clin Res. 2015;6(3):431. Scholar
  46. 46.
    Gilbert JM, Fitch KV, Grinspoon SK. HIV-related cardiovascular disease, statins, and the REPRIEVE Trial. Topics Antiviral Med. 2015;23(4):146–9.Google Scholar
  47. 47.
    Opondo PR, Ho-Foster AR, Ayugi J, Hatitchki B, Pumar M, Bilker WB, et al. HIV prevalence among hospitalized patients at the main psychiatric referral hospital in Botswana. AIDS Behav. 2017;
  48. 48.
    Gupta R, Dandu M, Packel L, Rutherford G, Leiter K, Phaladze N, et al. Depression and HIV in Botswana: a population-based study on gender-specific socioeconomic and behavioral correlates. PLoS One. 2010;5(12):e14252. Scholar
  49. 49.
    Acuda SW, Sebit MB. Serostatus surveillance testing of HIV-I infection among Zimbabwean psychiatric inpatients, in Zimbabwe. Central African J Med. 1996;42(9):254–7.Google Scholar
  50. 50.
    Lawler K, Mosepele M, Seloilwe E, Ratcliffe S, Steele K, Nthobatsang R, et al. Depression among HIV-positive individuals in Botswana: a behavioral surveillance. AIDS Behav. 2011;15(1):204–8. Scholar
  51. 51.
    •• Bernard C, Dabis F, de Rekeneire N. Prevalence and factors associated with depression in people living with HIV in sub-Saharan Africa: a systematic review and meta-analysis. PloS one. 2017;12(8):e0181960. This is a recent meta-analysis of all research in depression in sub-Saharan Africa. Main observations are that depression may affect as many as one third of HIV-infected patients, but screening and treatment is not yet well integrated into HIV programs. CrossRefPubMedPubMedCentralGoogle Scholar
  52. 52.
    Seth P, Kidder D, Pals S, Parent J, Mbatia R, Chesang K, et al. Psychosocial functioning and depressive symptoms among HIV-positive persons receiving care and treatment in Kenya, Namibia, and Tanzania. Prev Sci. 2014;15(3):318–28. Scholar
  53. 53.
    Ferrando SJ, Freyberg Z. Treatment of depression in HIV positive individuals: a critical review. Int Rev psychiatry (Abingdon, England). 2008;20(1):61–71.CrossRefGoogle Scholar
  54. 54.
    Belete T, Medfu G, Yemiyamrew E. Prevalence of HIV associated neurocognitive deficit among HIV positive people in Ethiopia: a cross sectional study at Ayder referral hospital. Ethiopian J Health Sci. 2017;27(1):67–76. Scholar
  55. 55.
    Habib AG, Yakasai AM, Owolabi LF, Ibrahim A, Habib ZG, Gudaji M, et al. Neurocognitive impairment in HIV-1-infected adults in Sub-Saharan Africa: a systematic review and meta-analysis. Int J Infect Dis. 2013;17(10):e820–31. Scholar
  56. 56.
    Lawler K, Jeremiah K, Mosepele M, Ratcliffe SJ, Cherry C, Seloilwe E, et al. Neurobehavioral effects in HIV-positive individuals receiving highly active antiretroviral therapy (HAART) in Gaborone, Botswana. PLoS One. 2011;6(2):e17233. Scholar
  57. 57.
    Vujkovic M, Bellamy SL, Zuppa AF, Gastonguay M, Moorthy GS, Ratshaa BR, et al. Brief Report: CYP2B6 516G>T Minor allele protective of late virologic failure in Efavirenz-treated HIV-infected patients in Botswana. J Acquir Immune Defic Syndr (1999). 2017;75(4):488–91. Scholar
  58. 58.
    Ahmed MH, Noor SK, Bushara SO, Husain NE, Elmadhoun WM, Ginawi IA, et al. Non-alcoholic fatty liver disease in Africa and Middle East: an attempt to predict the present and future implications on the healthcare system. Gastroenterol Res. 2017;10(5):271–9. Scholar
  59. 59.
    Vinikoor MJ, Sinkala E, Mweemba A, Zanolini A, Mulenga L, Sikazwe I, et al. Elevated AST-to-platelet ratio index is associated with increased all-cause mortality among HIV-infected adults in Zambia. Liver Int. 2015;35(7):1886–92. Scholar
  60. 60.
    Wandeler G, Mulenga L, Vinikoor MJ, Kovari H, Battegay M, Calmy A, et al. Liver fibrosis in treatment-naive HIV-infected and HIV/HBV co-infected patients: Zambia and Switzerland compared. Int J Infect Dis. 2016;51:97–102. Scholar
  61. 61.
    Masimango MI, Sumaili EK, Jadoul M, Wallemacq P, Mubagwa DK, Makulo RJ, et al. Prevalence of microalbuminuria and diagnostic value of dipstick proteinuria in outpatients from HIV clinics in Bukavu, the Democratic Republic of Congo. BMC Nephrol. 2014;15(1):146. Scholar
  62. 62.
    Shabbal DM, Jamda MA, Dalhatu IT, Abdulrahman MB, Isichei C. Comparison of microalbuminuria among treatment naive HIV sero-positive and negative adult clients in Faith Alive Foundation Hospital, Jos. Niger Med J. 2014;55(6):508–11. Scholar
  63. 63.
    Falasca K, Di Nicola M, Porfilio I, Ucciferri C, Schiaroli E, Gabrielli C, et al. Predictive factors and prevalence of microalbuminuria in HIV-infected patients: a cross-sectional analysis. BMC Nephrol. 2017;18(1):255. Scholar
  64. 64.
    Hadigan C, Edwards E, Rosenberg A, Purdy JB, Fleischman E, Howard L, et al. Microalbuminuria in HIV disease. Am J Nephrol. 2013;37(5):443–51. Scholar
  65. 65.
    Szczech LA, Gange SJ, van der Horst C, Bartlett JA, Young M, Cohen MH, et al. Predictors of proteinuria and renal failure among women with HIV infection. Kidney Int. 2002;61(1):195–202. Scholar
  66. 66.
    Wyatt CM, Hoover DR, Shi Q, Seaberg E, Wei C, Tien PC, et al. Microalbuminuria is associated with all-cause and AIDS mortality in women with HIV infection. J Acquir Immune Defic Syndr (1999). 2010;55(1):73–7. Scholar
  67. 67.
    Choi AI, Li Y, Deeks SG, Grunfeld C, Volberding PA, Shlipak MG. Association between kidney function and albuminuria with cardiovascular events in HIV-infected persons. Circulation. 2010;121(5):651–8. Scholar
  68. 68.
    Adebamowo CA, Casper C, Bhatia K, Mbulaiteye SM, Sasco AJ, Phipps W, et al. Challenges in the detection, prevention, and treatment of HIV-associated malignancies in low- and middle-income countries in Africa. J Acquir Immune Defic Syndr (1999). 2014;67(Suppl 1):S17–26. Scholar
  69. 69.
    Goeieman BJ, Firnhaber CS, Jong E, Michelow P, Kegorilwe P, Swarts A, et al. Prevalence of anal HPV and anal dysplasia in HIV-infected women from Johannesburg, South Africa. J Acquir Immune Defic Syndr (1999). 2017;75(3):e59–64. Scholar
  70. 70.
    •• Buyego P, Nakiyingi L, Ddungu H, Walimbwa S, Nalwanga D, Reynolds SJ, et al. Possible misdiagnosis of HIV associated lymphoma as tuberculosis among patients attending Uganda Cancer Institute. AIDS Res Ther. 2017;14(1):13. This is an important real work report of the high rates of lymphoma misdiagnosis, probably from availability bias (error in clinical reasoning). The publication highlights the need for tissue diagnosis in a setting where clinical presentation of malignancies may mimic prevalent infections. CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Internal Medicine, Office F4069 Faculty of MedicineUniversity of BotswanaGaboroneBotswana

Personalised recommendations